Associated Papers
Mouse model of atypical DAT deficiency syndrome uncovers dopamine dysfunction associated with parkinsonism and ADHD.
Herborg F et al.
The Journal of Clinical Investigation, 2026
Kappa opioid receptor antagonism restores phosphorylation, trafficking and behavior induced by a disease-associated dopamine transporter variant.
Mayer FP et al.
Molecular Psychiatry, 2025
The Ins and Outs of Dopamine Transporter Gene Manipulation: In Vivo Models of DAT Dysfunction.
Stewart A et al.
Advances in Neurobiology, 2025
Kappa Opioid Receptor Antagonism Restores Phosphorylation, Trafficking and Behavior induced by a Disease Associated Dopamine Transporter Variant.
Mayer FP et al.
Biorxiv : the Preprint Server for Biology, 2024
Leaky lessons learned: Efflux prone dopamine transporter variant reveals sex and circuit specific contributions of D2 receptor signalling to neuropsychiatric disease.
Mayer FP et al.
Basic & Clinical Pharmacology & Toxicology, 2024
Dopamine Transporter Deficiency Syndrome (DTDS): Expanding the Clinical Phenotype and Precision Medicine Approaches.
Ng J et al.
Cells, 2023
Phenotypes and Genotypes of Inherited Disorders of Biogenic Amine Neurotransmitter Metabolism.
Mastrangelo M et al.
Genes, 2023
The dopamine transporter gene SLC6A3: multidisease risks.
Reith MEA et al.
Molecular Psychiatry, 2022
Functional and Biochemical Consequences of Disease Variants in Neurotransmitter Transporters: A Special Emphasis on Folding and Trafficking Deficits.
Bhat S et al.
Pharmacology & Therapeutics, 2021
Psychomotor impairments and therapeutic implications revealed by a mutation associated with infantile Parkinsonism-Dystonia.
Aguilar JI et al.
Elife, 2021
Neuropsychiatric disease-associated genetic variants of the dopamine transporter display heterogeneous molecular phenotypes.
Herborg F et al.
The Journal of Biological Chemistry, 2018
Thermodynamic Coupling Function Analysis of Allosteric Mechanisms in the Human Dopamine Transporter.
LeVine MV et al.
Biophysical Journal, 2018
SLC6 Transporter Folding Diseases and Pharmacochaperoning.
Freissmuth M et al.
Handbook of Experimental Pharmacology, 2018
The second sodium site in the dopamine transporter controls cation permeation and is regulated by chloride.
Borre L et al.
The Journal of Biological Chemistry, 2014
Missense dopamine transporter mutations associate with adult parkinsonism and ADHD.
Hansen FH et al.
The Journal of Clinical Investigation, 2014
Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood.
Ng J et al.
Brain : a Journal of Neurology, 2014